OPDIVO VERSCU Trademark

Trademark Overview

On Wednesday, November 6, 2019, a trademark application was filed for OPDIVO VERSCU with the United States Patent and Trademark Office. The USPTO has given the OPDIVO VERSCU trademark a serial number of 88681636. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, November 27, 2023. This trademark is owned by Bristol-Myers Squibb Company. The OPDIVO VERSCU trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, including T Cell therapy; P...
opdivo verscu

General Information

Serial Number88681636
Word MarkOPDIVO VERSCU
Filing DateWednesday, November 6, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, November 27, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 1, 2020

Trademark Statements

Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, including T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, November 13, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543
Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Trademark Events

Event DateEvent Description
Monday, November 27, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, November 27, 2023ABANDONMENT - NO USE STATEMENT FILED
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, April 11, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 10, 2023SOU EXTENSION 5 GRANTED
Thursday, April 6, 2023SOU EXTENSION 5 FILED
Thursday, April 6, 2023SOU TEAS EXTENSION RECEIVED
Friday, February 3, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, February 2, 2023SOU EXTENSION 4 GRANTED
Thursday, October 27, 2022SOU EXTENSION 4 FILED
Wednesday, February 1, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, November 30, 2022NOTICE OF REVIVAL - E-MAILED
Wednesday, November 30, 2022SOU EXTENSION RECEIVED WITH TEAS PETITION
Wednesday, November 30, 2022PETITION TO REVIVE-GRANTED
Wednesday, November 30, 2022TEAS PETITION TO REVIVE RECEIVED
Monday, November 28, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, November 28, 2022ABANDONMENT - NO USE STATEMENT FILED
Tuesday, April 12, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, April 8, 2022SOU EXTENSION 3 GRANTED
Friday, April 8, 2022SOU EXTENSION 3 FILED
Friday, April 8, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, October 27, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 25, 2021SOU EXTENSION 2 GRANTED
Monday, October 25, 2021SOU EXTENSION 2 FILED
Monday, October 25, 2021SOU TEAS EXTENSION RECEIVED
Thursday, April 1, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 30, 2021SOU EXTENSION 1 GRANTED
Tuesday, March 30, 2021SOU EXTENSION 1 FILED
Tuesday, March 30, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, October 27, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 1, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 1, 2020PUBLISHED FOR OPPOSITION
Wednesday, August 12, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 28, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, July 27, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Sunday, July 26, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Sunday, July 26, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, January 29, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, January 29, 2020NON-FINAL ACTION E-MAILED
Wednesday, January 29, 2020NON-FINAL ACTION WRITTEN
Friday, January 24, 2020ASSIGNED TO EXAMINER
Wednesday, November 13, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, November 9, 2019NEW APPLICATION ENTERED

Related Keywords

verscu opdivo diseases pharmaceutical human preparations anti disorders system cancer treatment immune